$HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Daniel J. Hicklin
CEO
46
Employees
$0.36
Current Price
$34.91M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $44,749.39 | 143,199 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 20 | $727,780.60 | 2,006,677 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 45 | $1,783,872.82 | 3,781,610 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Sale | 5,812 | $0.67 | $3,894.04 | View Details |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Sale | 94,432 | $0.64 | $60,436.48 | View Details |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Sale | 6,719 | $0.64 | $4,300.16 | View Details |
| May 6, 2026 | EVNIN LUKE Director | Sale | 14,635 | $0.66 | $9,659.10 | View Details |
| May 7, 2026 | EVNIN LUKE Director | Sale | 79,086 | $0.63 | $49,824.18 | View Details |
| May 5, 2026 | EVNIN LUKE Director | Sale | 6,860 | $0.69 | $4,733.40 | View Details |
| May 4, 2026 | EVNIN LUKE Director | Sale | 47,963 | $0.72 | $34,533.36 | View Details |
116 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 41โ47 of 47 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$PBLS โ Parabilis Medicines, Inc.via RA CAPITAL MANAGEMENT, L.P.$ACET โ Adicet Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$ETNB โ 89bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$ARTV โ Artiva Biotherapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$JANX โ Janux Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.